193 related articles for article (PubMed ID: 25938427)
1. Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
Tang L; Tong R; Coyle VJ; Yin Q; Pondenis H; Borst LB; Cheng J; Fan TM
ACS Nano; 2015 May; 9(5):5072-81. PubMed ID: 25938427
[TBL] [Abstract][Full Text] [Related]
2. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.
Dowling M; Samuelson J; Fadl-Alla B; Pondenis HC; Byrum M; Barger AM; Fan TM
PLoS One; 2019; 14(1):e0210297. PubMed ID: 30601866
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.
Xu W; Siddiqui IA; Nihal M; Pilla S; Rosenthal K; Mukhtar H; Gong S
Biomaterials; 2013 Jul; 34(21):5244-53. PubMed ID: 23582862
[TBL] [Abstract][Full Text] [Related]
5. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
Kim D; Jeong YY; Jon S
ACS Nano; 2010 Jul; 4(7):3689-96. PubMed ID: 20550178
[TBL] [Abstract][Full Text] [Related]
6. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
7. Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.
Yin Q; Tang L; Cai K; Tong R; Sternberg R; Yang X; Dobrucki LW; Borst LB; Kamstock D; Song Z; Helferich WG; Cheng J; Fan TM
Proc Natl Acad Sci U S A; 2016 Aug; 113(32):E4601-9. PubMed ID: 27457945
[TBL] [Abstract][Full Text] [Related]
8. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
11. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
[TBL] [Abstract][Full Text] [Related]
12. Polylactide nanoparticles containing stably incorporated cyanine dyes for in vitro and in vivo imaging applications.
Tong R; Coyle VJ; Tang L; Barger AM; Fan TM; Cheng J
Microsc Res Tech; 2010 Sep; 73(9):901-9. PubMed ID: 20146347
[TBL] [Abstract][Full Text] [Related]
13. Albumin as a "Trojan Horse" for polymeric nanoconjugate transendothelial transport across tumor vasculatures for improved cancer targeting.
Yin Q; Tang L; Cai K; Yang X; Yin L; Zhang Y; Dobrucki LW; Helferich WG; Fan TM; Cheng J
Biomater Sci; 2018 May; 6(5):1189-1200. PubMed ID: 29570190
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
15. Ring-opening polymerization-mediated controlled formulation of polylactide-drug nanoparticles.
Tong R; Cheng J
J Am Chem Soc; 2009 Apr; 131(13):4744-54. PubMed ID: 19281160
[TBL] [Abstract][Full Text] [Related]
16. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy.
Luo YL; Shiao YS; Huang YF
ACS Nano; 2011 Oct; 5(10):7796-804. PubMed ID: 21942498
[TBL] [Abstract][Full Text] [Related]
17. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
[TBL] [Abstract][Full Text] [Related]
18. Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic.
Pearce AK; Simpson JD; Fletcher NL; Houston ZH; Fuchs AV; Russell PJ; Whittaker AK; Thurecht KJ
Biomaterials; 2017 Oct; 141():330-339. PubMed ID: 28711780
[TBL] [Abstract][Full Text] [Related]
19. The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells.
Tong R; Yala L; Fan TM; Cheng J
Biomaterials; 2010 Apr; 31(11):3043-53. PubMed ID: 20122727
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
